# Natrunix in Combination With Methotrexate for Rheumatoid Arthritis Treatment

> **NCT06590090** · PHASE2 · NOT_YET_RECRUITING · sponsor: **XBiotech, Inc.** · enrollment: 108 (estimated)

## Conditions studied

- Rheumatoid Arthritis

## Interventions

- **BIOLOGICAL:** Natrunix 400 mg
- **DRUG:** Placebo
- **DRUG:** Methotrexate (MTX)

## Key facts

- **NCT ID:** NCT06590090
- **Lead sponsor:** XBiotech, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-07-15
- **Primary completion:** 2027-01-15
- **Final completion:** 2027-07-15
- **Target enrollment:** 108 (ESTIMATED)
- **Last updated:** 2025-12-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06590090

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06590090, "Natrunix in Combination With Methotrexate for Rheumatoid Arthritis Treatment". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT06590090. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*